The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Suponeva N.A.

Research Center of Neurology

Davydov O.S.

Institute of General Pathology and Pathophysiology

Iskra D.A.

Saint Petersburg State Pediatric Medical University

Strokov I.A.

Sechenov First Moscow State Medical University (Sechenov University)

Khramilin V.N.

Pirogov Russian National Research Medical University

Churyukanov M.V.

Sechenov First Moscow State Medical University

Expert Panel opinion «Possibilities of Cytoflavin in Patients with Diabetic Polyneuropathy» based on the results of the study «Efficacy and safety of combined metabolic medication containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multiple-center randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)»

Authors:

Kukushkin M.L., Suponeva N.A., Davydov O.S., Iskra D.A., Strokov I.A., Khramilin V.N., Churyukanov M.V.

More about the authors

Journal: Russian Journal of Pain. 2023;21(3): 59‑65

DOI: 10.17116/pain20232103159

Views: 4133

Downloaded: 118

Download PDF (RU)
Contact the author
Table of contents

EXPERT PANEL OPINION «POSSIBILITIES OF CYTOFLAVIN IN PATIENTS WITH DIABETIC POLYNEUROPATHY» BASED ON THE RESULTS OF THE STUDY «EFFICACY AND SAFETY OF COMBINED METABOLIC MEDICATION CONTAINING INOSINE, NICOTINAMIDE, RIBOFLAVIN AND SUCCINIC ACID, FOR THE TREATMENT OF DIABETIC NEUROPATHY: A MULTIPLE-CENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP CLINICAL TRIAL (CYLINDER)»
EXPERT PANEL OPINION «POSSIBILITIES OF CYTOFLAVIN IN PATIENTS WITH DIABETIC POLYNEUROPATHY» BASED ON THE RESULTS OF THE STUDY «EFFICACY AND SAFETY OF COMBINED METABOLIC MEDICATION CONTAINING INOSINE, NICOTINAMIDE, RIBOFLAVIN AND SUCCINIC ACID, FOR THE TREATMENT OF DIABETIC NEUROPATHY: A MULTIPLE-CENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP CLINICAL TRIAL (CYLINDER)»

To cite this article:

Kukushkin ML, Suponeva NA, Davydov OS, Iskra DA, Strokov IA, Khramilin VN, Churyukanov MV. Expert Panel opinion «Possibilities of Cytoflavin in Patients with Diabetic Polyneuropathy» based on the results of the study «Efficacy and safety of combined metabolic medication containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multiple-center randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)». Russian Journal of Pain. 2023;21(3):59‑65. (In Russ.)
https://doi.org/10.17116/pain20232103159

 
Подписка 2025-2 (Russian Journal of Pain)
МСФ на ЯМ
Close metadata

Expert Panel opinion «Possibilities of Cytoflavin in Patients with Diabetic Polyneuropathy» based on the results of the study «Efficacy and safety of combined metabolic medication containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multiple-center randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER)».

Authors:

Kukushkin M.L.

Research Institute of General Pathology and Pathophysiology

Suponeva N.A.

Research Center of Neurology

Davydov O.S.

Institute of General Pathology and Pathophysiology

Iskra D.A.

Saint Petersburg State Pediatric Medical University

Strokov I.A.

Sechenov First Moscow State Medical University (Sechenov University)

Khramilin V.N.

Pirogov Russian National Research Medical University

Churyukanov M.V.

Sechenov First Moscow State Medical University

Received:

27.05.2023

Accepted:

03.06.2023

List of references:

  1. Dedov II, Shestakova MV, Mayorov AY, Vikulova OK, Galstyan GR, Kuraeva TL, Peterkova VA, Smirnova OM, Starostina EG, Surkova EV, Sukhareva OY, Tokmakova AY, Shamkhalova MS, Jarek-Martynova IR, Artemova EV, Beshlieva DD, Bondarenko ON, Volevodz NN, Grigoryan OR, Gomova IS, Dzhemilova ZN, Esayan RM, Ibragimova LI, Kalashnikov VY, Kononenko IV, Laptev DN, Lipatov DV, Motovilin OG, Nikonova TV, Rozhivanov RV, Shestakova EA. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes Mellitus. 2019;22(1S1):1-144. (In Russ.). https://doi.org/10.14341/DM221S1
  2. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal Diabetes Register data of 01.01.21. Diabetes Mellitus. 2021;24(3):204-221. (In Russ.). https://doi.org/10.14341/DM12759
  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853. 
  4. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014; 14:528.  https://doi.org/10.1007/s11892-014-0528-7
  5. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2020;5(1):42.  https://doi.org/10.1038/s41572-019-0097-9
  6. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, Broglio L, Granieri E, Lauria G. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131:1912-1925. https://doi.org/10.1093/brain/awn093
  7. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, on behalf of the Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-2293. https://doi.org/10.2337/dc10-1303
  8. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D.. Diabetic Neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154.  https://doi.org/10.2337/dc16-2042
  9. Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D, Cruccu G, Skljarevski V, Freynhagen R. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” — a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616-2625. https://doi.org/10.1016/j.pain.2013.05.043
  10. Davydov OS, Yakhno NN, Kukushkin ML, Churukanov MV, Abuzarova GR, Amelin AV, Balyazin VA, Barantsevich ER, Barinov AN, Barulin AE, Bel’skaya GN, Bykov YuN, Danilov AB, Doronina OB, Dreval ON, Evseev MA, Zagorul’ko OI, Isagulyan ED, Kalinskiy PP, Karakulova YuV, Karateev AE, Kopenkin SS, Kurushina OV, Medvedeva LA, Parfenov VA, Sergienko DA, Strokov IA, Khabirov FA, Shirokov VA. Neuropathic pain: clinical guidelines on the diagnostics and treatment from the Russian Association for the Studying of Pain. Russian Journal of Pain. 2018;4(58):5-41. (In Russ.). https://doi.org/10.25731/RASP.2018.04.025
  11. Pop-Busui R, Ang L, Boulton AJM, et al. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy. ADA Clinical Compendia. 2022; 2022(1):1-32.  https://doi.org/10.2337/db2022-01
  12. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJG. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: A meta-analysis of randomized controlled trials. Int J Endocrinology. 2012;2012:456279. https://doi.org/10.1155/2012/456279
  13. Ziegler D, Tesfaye S, Spallone V, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2022;186:109063. Published: September 18, 2021. https://doi.org/10.1016/j.diabres.2021.109063
  14. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Sys Rev. 2012;6(6):CD007543. https://doi.org/10.1002/14651858.cd007543.pub2
  15. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358(24):2630-2633.
  16. Rossboth S, Rossboth B, Schoenherr H, Lechleitner M, Oberaigner W. Risk factors for diabetic foot complications among patients with type 2 diabetes in Austria. A registry-based retrospective cohort study. Endocrinol Diab Metab. 2021;4:e00286. https://doi.org/10.1002/edm2.286
  17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.  https://doi.org/10.1038/414813a
  18. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54(6):1615-1625.
  19. Strokov IA, Melnichenko GA, Albekova ZS, Zilov AV, Akhmedzhanova LT. The prevalence and risk factors of diabetic polyneuropathy in inpatients with type 1 diabetes. Neuromuscular Diseases. 2012;1:25-31. (In Russ.). https://doi.org/10.17650/2222-8721-2012-0-1-25-31
  20. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circulation Research. 2016;11:1808-1829.
  21. Ziegler D. Current Concepts in the Management of Diabetic Polyneuropathy. Neuromuscular Diseases. 2012;2:7-19. (In Russ.). https://doi.org/10.17650/2222-8721-2012-0-2-7-19
  22. Smirnov AV, Nesterova OB, Golubev RV. Succinic acid and its application in medicine. Part I. Succinic acid: metabolite and regulator of metabolism of the human body. Nephrology. 2014;18(2);33-41. (In Russ.).
  23. Smirnov AV, Nesterova OB, Golubev RV. Succinic acid and its application in medicine. Part II. Application of succinic acid in medicine. Nephrology. 2014;18(4);12-24. (In Russ.).
  24. Bilichenko SV, Savateyeva-Lyubimova TN, Savateyev AV. Influence of cytoflavin on memory and neuromuscular transmission in rats with alloxane diabetes. Herald of the Mechnikov Saint-Petersburg State Medical Academy. 2009;1(30):129-132. (In Russ.).
  25. Volchegorskiy IA, Rassokhina LM, Ermakova SG, Miroshnichenko IYu. Protective effect of cytoflavin and its components in mice with acute alloxan intoxication. Experimental and Clinical Pharmacology. 2013;76(4):26-31. (In Russ.).
  26. Volchegorskiy IA, Rassokhina LM, Miroshnichenko IYu. Antihypoxic effect of 3-hydroxypyridine and succinic acid derivatives and their nootropic action on alloxan diabetes. Experimental and Clinical Pharmacology. 2011;74(12):27-32. (In Russ.).
  27. Abdelkader NF, Ibrahima SM, Moustafa PE, et al. Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TGF-β/PKC/TRPV1 signaling pathways. Biomedicine & Pharmacotherapy. 2022;145:112395.
  28. Kodentsova VM, Vrzhesinskaya OA, Spirichev VB. The exchange of vitamins in diabetes. Problems of Endocrinology. 2000;46(5):39-45. (In Russ.).
  29. Fadeeva NI, Balabolkin MI, Mamaeva GG, Kravchenko TV, Mishchenko BP, Knyazeva AP. Application of nicotinamide and other antioxidant drugs in complex therapy of 2-type diabetes. Diabetes Mellitus. 2001;4(1):21-23. (In Russ.).
  30. Ekusheva EV, Voitenkov VB, Rizakhanova OA. The effectiveness of cytoflavin in complex therapy of patients with the coronavirus infection COVID-19. Korsakov Journal of Neurology and Psychiatry. 2021;121(12):33-39. (In Russ.).
  31. Putilina MV, Teplova NV, Bairova KI, Petrikeeva AE, Shabalina NI. The result of prospective randomized study CITADEL — the efficacy and safety of drug cytoflavin in postcovid rehabilitation. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10):45-51. (In Russ.). https://doi.org/10.17116/jnevro202112110145
  32. Zhuravleva MV, Gorodetskaya GI, Reznikova TS, Vasyukova NS, Arkhipov VV, Serebrova SYu. Meta-analytical evaluation of the clinical efficacy of a complex metabolic neuroprotector in patients with chronic cerebral ischemia. Antibiotics and Chemotherapy. 2021;66(9-10):39-53. (In Russ.).
  33. Kovalenko AL, Nagibovich OA, Vishnevsky AYu, Belekhov GA, Gubaidullin RR, Popov DV, Agafiina AS. Use of a neurometabolism-targeting drug in prevention of postoperative cognitive dysfunction. General Reanimatology. 2022;18(2):12-21. (In Russ.).
  34. Skripko VD, Churpiy IK, Mykhailoiko IYa, Kovalenko AL, Talikova EV. Cytophlavin inclusion in complex treatment of diabetic foot syndrome with signs of lower limb blood vessels medicalcinosis. Pirogov Russian Journal of Surgery. 2018;10:69-72. (In Russ.).
  35. Sakovych VN, Ahmad Abed al Raheem Abdallah Aqrabawi. Metabolic support effectiveness in treatment of non-proliferative diabetic retinopathy. Ophthalmology. Eastern Europe. 2016;6(2):263-273. (In Russ.).
  36. Kharitonova TV, Semenova OI, Kovalenko AL, Kondakova VA. The role of cytoflavin in combination therapy of complicated type 2 diabetes. Experimental and Clinical Pharmacology. 2019;82(9):15-19. (In Russ.).
  37. Gatskikh IV, Petrova MM, Shalda TP, Varygina EL, Kuznetsov MN, Narkevich AN. Dynamics of cognitive disorders in patients with type 2 diabetes mellitus under effect of metabolic therapy. Clinical Medicine. 2016; 94(7):533-539. (In Russ.).
  38. Shchepankevich LA, Pervuninskaya MA, Gribacheva IA, Popova TF, Nikolaev YuA, Taneeva EV, Petrova EV, Shchepankevich MS. The role of inflammation in the development of diabetic polyneuropathy and the possibility of its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2023; 123(4):68-71. (In Russ.). https://doi.org/10.17116/jnevro202312304168

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.